According to our research, MaR1 therapy altered the NRF2 pathway specifically for cystine–glutamate antiporter (SLC7A11)/GPX4 signals to protect osteoblasts from ferroptosis in T2DM so as to ameliorate osteogenesis in T2DOP. Here, GPX4 is linked to type 2 diabetes mellitus.